Agios Pharmaceuticals (NASDAQ:AGIO) Price Target Raised to $55.00

Agios Pharmaceuticals (NASDAQ:AGIO) had its price objective boosted by Royal Bank of Canada from $53.00 to $55.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s price objective points to a potential upside of 25.11% from the stock’s current price.

A number of other equities analysts have also commented on AGIO. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Monday, June 17th. The Goldman Sachs Group increased their price target on Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a “neutral” rating in a report on Tuesday, June 4th. StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, July 11th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and set a $46.00 target price on shares of Agios Pharmaceuticals in a research note on Thursday, June 13th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $51.33.

Agios Pharmaceuticals Stock Performance

Shares of AGIO stock traded down $0.54 during trading hours on Friday, reaching $43.96. The company had a trading volume of 511,491 shares, compared to its average volume of 786,415. The stock’s fifty day simple moving average is $44.23 and its 200 day simple moving average is $34.32. The company has a market capitalization of $2.50 billion, a P/E ratio of -6.98 and a beta of 0.79. Agios Pharmaceuticals has a twelve month low of $19.80 and a twelve month high of $50.35.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.58) by ($0.11). Agios Pharmaceuticals had a negative net margin of 1,199.26% and a negative return on equity of 41.41%. The firm had revenue of $8.60 million during the quarter, compared to analyst estimates of $9.34 million. During the same period last year, the business earned ($1.51) EPS. The firm’s revenue was up 28.4% compared to the same quarter last year. As a group, equities analysts expect that Agios Pharmaceuticals will post -2.15 earnings per share for the current year.

Institutional Trading of Agios Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. Quest Partners LLC acquired a new position in shares of Agios Pharmaceuticals in the 4th quarter worth approximately $41,000. China Universal Asset Management Co. Ltd. boosted its holdings in Agios Pharmaceuticals by 352.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,469 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 5,040 shares during the period. NEOS Investment Management LLC bought a new stake in Agios Pharmaceuticals during the fourth quarter valued at $210,000. Northcape Wealth Management LLC acquired a new stake in shares of Agios Pharmaceuticals during the second quarter worth $244,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Agios Pharmaceuticals by 9.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,444 shares of the biopharmaceutical company’s stock worth $255,000 after buying an additional 942 shares during the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.